BiotechTube

radio-labeled naquotinib + naquotinib

Phase 1Withdrawn
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Epidermal Growth Factor Receptor (EGFR) Mutations

Conditions

Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors

Trial Timeline

Nov 15, 2016 โ†’ Nov 15, 2016

NCT ID
NCT02674555

About radio-labeled naquotinib + naquotinib

radio-labeled naquotinib + naquotinib is a phase 1 stage product being developed by Astellas Pharma for Epidermal Growth Factor Receptor (EGFR) Mutations. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02674555. Target conditions include Epidermal Growth Factor Receptor (EGFR) Mutations, Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02674555Phase 1Withdrawn

Competing Products

13 competing products in Epidermal Growth Factor Receptor (EGFR) Mutations

See all competitors
ProductCompanyStageHype Score
HER3-DXdDaiichi SankyoPre-clinical
23
ErlotinibAstellas PharmaPhase 2
52
KRN23Kyowa KirinPhase 2
52
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
ABT-414AbbViePre-clinical
23
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3
77
Venetoclax + FulvestrantRochePhase 2
52
Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine + Paclitaxel, Bevacizumab, liposomal doxorubicin, CapecitabineRochePhase 3
77
Palbociclib + Everolimus + ExemestanePfizerPhase 1/2
40
PaliferminSwedish Orphan BiovitrumPhase 1/2
40
Crysvita (burosumab-twza) TreatmentUltragenyx PharmaceuticalApproved
80
FDX104 (4% Doxycycline)Vyne TherapeuticsPhase 2
44
ATR-04AzitraPhase 1/2
33

Other Products from Astellas Pharma

Tacrolimus, PrografยฎApproved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Mysleeยฎ) + placeboApproved
85
TacrolimusApproved
85